Intelligent Bio Solutions
INBS
Market cap $5.97M

1.36 USD

-0.12

8.11%

Updated Nov 18, 2:39 PM EST

1 day

-8.11%

5 days

-26.49%

1 month

-13.38%

3 months

18.26%

6 months

-44.49%

Year to date

-65.66%

1 year

-62.22%

5 years

-99.95%

10 years

-99.95%

About: Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Employees: 48

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 8 [Q2] → 8 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

4.17% less ownership

Funds ownership: 10.11% [Q2] → 5.94% (-4.17%) [Q3]

28% less capital invested

Capital invested by funds: $606K [Q2] → $437K (-$169K) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for INBS.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about INBS published over the past 30 days

Zacks Investment Research

INBS Stock Declines Despite Positive Results of Pharmacokinetic Study

Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.

INBS Stock Declines Despite Positive Results of Pharmacokinetic Study

Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS' patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.

Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach

Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal first quarter ended September 30, 2024. The Company expects unaudited revenue of approximately $0.87 million for the three months ended September 30, 2024, representing an increase of 10% year-on-year and 20% quarter-on-quarter.

Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles

New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the upcoming LD Micro Main Event XVII on October 28-30, 2024, in Los Angeles. LD Micro Main Event XVII Dates: October 28-30, 2024 Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Presentation Day and Time: October 30 at 10:00 a.m.

Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles

Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity

Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency, with prominent clients across a wide range of industries, including mining, transportation and construction. Spirit Group will bring INBS' Intelligent Fingerprinting Drug Testing Solution to government and corporate clients across Australia.

Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution

GPS Marine Adopts Intelligent Bio Solutions' Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services

INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.

GPS Marine Adopts Intelligent Bio Solutions' Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company's clinical study plan.

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

UK's Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions' Fingerprint Drug Test to Enhance Workplace Safety

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK's largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing.

UK's Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions' Fingerprint Drug Test to Enhance Workplace Safety

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update.

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

See News Rankings

Charts implemented using Lightweight Charts™